Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07509008 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Sep 1, 2026 to Aug 11, 2026 · Interventions: Cyclophosphamide (Drug), Fludarabine (Drug), Rimiducid (AP1903) (Drug), TGFBR2 KO CAR27/IL-15 NK cells (Drug) to Cyclophosphamide (Drug), Fludarabine (Drug), Rimiducid (AP1903) (Drug), TGFBR2 KO CAR27/IL-15 NK cells (Drug) · Eligibility criteria expanded, about 34 words · 2 more Show 5 more changesShow less
    • Start date changed from estimate of Sep 1, 2026 to Aug 11, 2026
    • Interventions: Cyclophosphamide (Drug), Fludarabine (Drug), Rimiducid (AP1903) (Drug), TGFBR2 KO CAR27/IL-15 NK cells (Drug) to Cyclophosphamide (Drug), Fludarabine (Drug), Rimiducid (AP1903) (Drug), TGFBR2 KO CAR27/IL-15 NK cells (Drug)
    • Eligibility criteria expanded, about 34 words
    • Study description expanded, about 10 words
    • Site details revised
  2. 2 versions Re-verified since Apr 29, 2026, no change to tracked fieldsv2-v3
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical research study is to study the recommended dose of TROP2 CAR/IL-15 TGFBR2 KO NK cells that can be given intraperitoneally (infused directly into the stomach area) to participants with adenocarcinoma of the stomach that has spread to the peritoneum. The safety and effectiveness of this treatment will also be studied.
Trial Details
NCT Number NCT07509008
Lead Sponsor M.D. Anderson Cancer Center
Conditions Gastric Cancer, Metastatic
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov